Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) reported its financial results for the second quarter of fiscal 2023, the period ended June 30, revealing a slight year-over-year improvement in revenue – up by 1.5% to $22.1 million.

"During the first half of 2023, we successfully launched our branded licensing initiative in our cannabis sector," Sean Sand, the company's CFO, said. "Sales have exceeded our expectations and we look forward to continuing our licensing efforts in the space."

Irwin is an herbal supplement formulator and leader in the nutrition industry at the forefront of the "psychedelics renaissance." It is also considered one of world's largest seller of CBD in the mass market. Klee Irwin, who serves as the company's CEO and chairman, spoke at last year's Benzinga Psychedelics Capital Conference.

Benzinga's cannabis event returns in Chicago next month, featuring top cannabis …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.